Company Overview and Share Capital
Cellectis is known for its pioneering work in gene editing and cell therapy, which has garnered considerable attention in the biopharmaceutical space. One key aspect of corporate governance for any publicly traded company, including Cellectis, is the ongoing communication about share capital and voting rights.
Current Share Capital Status
As of the end of September 2025, Cellectis reports a total of 100,325,229 shares in circulation. This figure reflects the company's growth and market presence, a testament to its dynamic approach to research and development.
Out of these shares, there are 89,413,272 voting rights conferred to shareholders. This voting capacity allows investors a voice in corporate decisions, shaping the company's future direction.
Voting Rights Explained
The number of voting rights associated with the shares plays a crucial role in a company’s governance. It enables shareholders to participate in decision-making processes such as electing board members and approving significant motions. Cellectis actively encourages shareholder participation in its meetings to ensure transparency and stakeholder engagement.
Latest Updates on Shareholder Engagement
Cellectis strives to maintain an open dialogue with its investors, reflecting a fundamental commitment to shareholder interests. The company recognizes the critical role that informed shareholders play in its success, which is reflected in regular updates on key metrics like share capital and voting rights.
This transparency not only builds trust but also aligns with best practices in corporate governance. As the landscape of biotechnology evolves, maintaining a robust framework for shareholder communication remains paramount.
Investor Relations Focus
For more detailed inquiries, Cellectis encourages interested parties to reach out directly to its Investor Relations team. With a dedicated team led by Arthur Stril, the Chief Financial Officer and Chief Business Officer, the company is ready to address any queries regarding its financials and corporate strategies.
Contact Information
Cellectis has established several key contacts for media and investor relations:
For media inquiries, Pascalyne Wilson, the Director of Communications, is available at +33 (0)7 76 99 14 33, or via email at media@cellectis.com.
For investor relations, Arthur Stril is reachable through investors@cellectis.com, ready to provide insights into corporate governance and shareholdings.
Frequently Asked Questions
What is the current number of shares for Cellectis?
As of September 2025, Cellectis has 100,325,229 shares in circulation.
How many voting rights are there for shareholders?
Cellectis currently has 89,413,272 voting rights associated with its shares.
Who can shareholders contact for more information?
Shareholders can contact Pascalyne Wilson for media inquiries and Arthur Stril for investor relations.
Why is shareholder engagement important?
Shareholder engagement is crucial for maintaining transparency and ensuring that investors have a voice in the company's governance.
Where is Cellectis listed?
Cellectis is listed on the Euronext Growth market and has a presence in multiple locations, including the Nasdaq.
